Livforsakringsbolaget Skandia Omsesidigt Raises Holdings in Johnson & Johnson $JNJ

Key Points

• Livforsakringsbolaget Skandia Omsesidigt increased its Johnson & Johnson stake by 4.9% in the second quarter, adding 10,400 shares to hold 222,206 shares valued at approximately $56.4 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly earnings of $2.90 per share, beating estimates of $2.84, while revenue rose 6.6% year over year to $25.31 billion. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $272.83.
• The company declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and a 1.9% yield. Meanwhile, insiders sold 97,569 shares worth approximately $25.5 million over the past 90 days.

Livforsakringsbolaget Skandia Omsesidigt lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 222,206 shares of the company's stock after purchasing an additional 10,400 shares during the quarter. Johnson & Johnson comprises about 1.8% of Livforsakringsbolaget Skandia Omsesidigt's investment portfolio, making the stock its 11th biggest position. Livforsakringsbolaget Skandia Omsesidigt's holdings in Johnson & Johnson were worth $56,431,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Auto Owners Insurance Co increased its stake in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $6,924,523,000. Capital World Investors bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $2,005,942,000. Jupiter Topco LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $1,967,399,000. Finally, Diamant Asset Management Inc. increased its position in Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 97,569 shares of company stock worth $25,476,044 over the last ninety days. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the stock a "buy" rating in a report on Monday, July 6th. Leerink Partners raised shares of Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target for the company in a report on Wednesday, May 13th. Bank of America lifted their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a research report on Friday, July 10th. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $272.83.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $275.12 on Tuesday. The firm has a 50-day moving average price of $262.32 and a 200-day moving average price of $245.30. The firm has a market capitalization of $663.01 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm posted $2.77 EPS. The firm's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson's payout ratio is presently 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.